Presentation is loading. Please wait.

Presentation is loading. Please wait.

Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.

Published bySylvia Horn Modified over 6 years ago

Similar presentations

Presentation on theme: "Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug."— Presentation transcript:

1

2 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organisation with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners. © 2018 DIA, Inc. All rights reserved

3 Presentation Guidelines
 Keep number of slides to an absolute minimum  Do not read your slides  8 lines or less so people in the back of the room can read your slides  Avoid pictures/graphs/charts packed with small text  Use a maximum of 1-2 slides per minute  Use dark text with a light background  Keep animated text, sounds and fancy transitions to a minimum © 2018 DIA, Inc. All rights reserved

4 Disclosure Statement 
 I have no real or apparent relevant financial relationships to disclose  I am employed by a regulatory agency, and have nothing to disclose Please note that DIA is not requesting a numerical amount to be entered for any disclosure, please indicate by marking the check box, and then providing the company name only for those disclosures you may have. Will any of the relationships reported in the chart above impact your ability to present an unbiased presentation?  Yes  No In accordance with the ACPE requirements, if the disclosure statement is not completed or returned, participation in this activity will be refused. Type of Financial Interest within last 12 months Name of Commercial Interest Grants/Research Funding Stock Shareholder Consulting Fees Employee Other (Receipt of Intellectual Property Rights/Patent Holder, Speaker’s Bureau) © 2018 DIA, Inc. All rights reserved

5 © 2018 DIA, Inc. All rights reserved

6

Download ppt "Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug."

Similar presentations

Patients’ Perspective on HTA and Off-label use David Head MBA Chief Executive RP Fighting Blindness 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam.

Patients’ Perspective on HTA and Off-label use David Head MBA Chief Executive RP Fighting Blindness 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam.
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.

Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.
Introduction to Drug Rediscovery John Lisman Attorney-at-law Lisman Legal Life sciences Insert your logo in this area then delete this text box.

Introduction to Drug Rediscovery John Lisman Attorney-at-law Lisman Legal Life sciences Insert your logo in this area then delete this text box.
How to audit the role of the vendor in the conduct of outsourced studies Kristel Van de Voorde Director Global Quality Regulatory Compliance Bristol-Myers.

How to audit the role of the vendor in the conduct of outsourced studies Kristel Van de Voorde Director Global Quality Regulatory Compliance Bristol-Myers.
12341234 Presenter Name Title Organization Twitter Handle Insert your logo here, then delete text.

Presenter Name Title Organization Twitter Handle Insert your logo here, then delete text.
Click to add Presentation Title Arial 32, 5 line max title space line 3, title space line 4, title space line 5 Presenter Title Organization Insert your.

Click to add Presentation Title Arial 32, 5 line max title space line 3, title space line 4, title space line 5 Presenter Title Organization Insert your.
Title of the presentation

Title of the presentation
Financial Disclosures Financial interests, arrangements or affiliations that could be perceived as a real or apparent “conflict of interest” in the context.

Financial Disclosures Financial interests, arrangements or affiliations that could be perceived as a real or apparent “conflict of interest” in the context.
DISCLAIMER: The views and opinions expressed in this presentation are those of the author and do not necessarily represent official policy or position.

DISCLAIMER: The views and opinions expressed in this presentation are those of the author and do not necessarily represent official policy or position.
Strategic Analyses and Interpretation: Regulatory Intelligence for Decision Making Amy N. Grant Director, Regulatory Strategy & Science ViroPharma Incorporated.

Strategic Analyses and Interpretation: Regulatory Intelligence for Decision Making Amy N. Grant Director, Regulatory Strategy & Science ViroPharma Incorporated.
Good Laboratory Practices and Inspection Readiness Paul Swidersky President/Sr. Consultant Quality Associates, Inc.

Good Laboratory Practices and Inspection Readiness Paul Swidersky President/Sr. Consultant Quality Associates, Inc.
DIA ERS SIAC IND CMC eCTD Submissions Part II – IND to NDA

DIA ERS SIAC IND CMC eCTD Submissions Part II – IND to NDA
Process-based Metadata From a DIA Presentation: eTMF – Migrating from Paper Trial Master Files to Electronic Eldin Rammell, Managing Director, Rammell.

Process-based Metadata From a DIA Presentation: eTMF – Migrating from Paper Trial Master Files to Electronic Eldin Rammell, Managing Director, Rammell.
Experiences from building a lessons- learned database for regulatory interactions Åsa Rembratt Sr Reg Intelligence Manager Novo Nordisk A/S 26th Annual.

Experiences from building a lessons- learned database for regulatory interactions Åsa Rembratt Sr Reg Intelligence Manager Novo Nordisk A/S 26th Annual.
Group Sequential Tests for Delayed Responses Christopher Jennison Department of Mathematical Sciences University of Bath Lisa Hampson Department of Mathematics.

Group Sequential Tests for Delayed Responses Christopher Jennison Department of Mathematical Sciences University of Bath Lisa Hampson Department of Mathematics.
Financial Interest Disclosure (over the past 24 months) Commercial Interest Relationship Company A advisory board, consultant, investigator Company B speaker.

Financial Interest Disclosure (over the past 24 months) Commercial Interest Relationship Company A advisory board, consultant, investigator Company B speaker.
Making Comments Count for High-Impact Regulations and Guidelines in Canada, EU, Japan, and US Chairperson: Amy N. Grant Director, Regulatory Strategy &

Making Comments Count for High-Impact Regulations and Guidelines in Canada, EU, Japan, and US Chairperson: Amy N. Grant Director, Regulatory Strategy &
Gabor Fari Life Sciences Solution Strategist Microsoft Corporation

Gabor Fari Life Sciences Solution Strategist Microsoft Corporation
- A “Portable” Implementation

- A “Portable” Implementation
Mutagenic Impurities: Guidances Update w/ CMC Perspectives

Mutagenic Impurities: Guidances Update w/ CMC Perspectives

Similar presentations

Ads by Google